

Summary of Product Characteristics

1 NAME OF THE MEDICINAL PRODUCT

Zantac 150mg Film-coated Tablets

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Each film-coated tablet contains 150mg ranitidine (as hydrochloride).

For full list of excipients, *see section 6.1*.

3 PHARMACEUTICAL FORM

Film-coated tablet.

Product imported from the Netherlands and the UK:
White, round, biconvex tablets, engraved ‘GXEC2’ on one side and plain on the other.

4 CLINICAL PARTICULARS

As per PA1077/013/003

5 PHARMACOLOGICAL PROPERTIES

As per PA1077/013/003

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Microcrystalline cellulose
Magnesium stearate
Hypromellose
Titanium dioxide (E171)
Triacetin

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

The shelf-life expiry date of this product shall be the date shown on the container and outer package of the product on the market in the country of origin.

6.4 Special precautions for storage

Do not store above 25°C.
Store in the original package in order to protect from moisture.

6.5 Nature and contents of container

Blister/foil packs containing 60 tablets.

6.6 Special precautions for disposal of a used medicinal product or waste materials derived from such medicinal product and other handling of the product

No special requirements.

7 PARALLEL PRODUCT AUTHORISATION HOLDER

PCO Manufacturing
Unit 10, Ashbourne Business Park
Rath
Ashbourne
Co. Meath

8 PARALLEL PRODUCT AUTHORISATION NUMBER

PPA0465/033/001

9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 30 May 1995

Date of last renewal: 30 May 2010

10 DATE OF REVISION OF THE TEXT

December 2017